Alvotech (ALVO)

NASDAQ: ALVO · Real-Time Price · USD

8.30

-0.38 (-4.38%)

At close: Oct 9, 2025, 4:00 PM EDT

8.45

+0.15 (1.81%)

After-hours: Oct 9, 2025, 7:33 PM EDT

Alvotech Employees

Alvotech had 1,012 employees as of December 31, 2024. The number of employees increased by 13 or 1.30% compared to the previous year.

Employees

1,012

Change (1Y)

13

Growth (1Y)

1.30%

Revenue / Employee

$555,808

Profits / Employee

$62,607

Market Cap

2.60B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	1,012	13	1.30%
Dec 31, 2023	999	82	8.94%
Dec 31, 2022	917	133	16.96%
Dec 31, 2021	784	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ALVO News

3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
3 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
17 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
17 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
20 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
4 weeks ago - Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
5 weeks ago - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York - GlobeNewsWire
7 weeks ago - Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® - GlobeNewsWire